propylene glycol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4024	57-55-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: propane-1,2-diol 1,2-propanediol 1,2-propylene glycol propylene glycol	A clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations. Molecular weight: 76.10 Formula: C3H8O2 CLOGP: -1.06 LIPINSKI: 0 HAC: 2 HDO: 2 TPSA: 40.46 ALOGS: 1.10 ROTB: 1

Molecule

Description

Molfile Inchi Smiles

Synonyms:

propane-1,2-diol
1,2-propanediol
1,2-propylene glycol
propylene glycol

A clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations.

Molecular weight: 76.10
Formula: C3H8O2
CLOGP: -1.06
LIPINSKI: 0
HAC: 2
HDO: 2
TPSA: 40.46
ALOGS: 1.10
ROTB: 1

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
None	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Eye irritation	192.10	19.65	62	2993	21909	63464058
Eye pain	80.38	19.65	37	3018	33817	63452150
Foreign body sensation in eyes	79.49	19.65	19	3036	2215	63483752
Ocular hyperaemia	70.90	19.65	31	3024	25113	63460854
Pneumonia viral	63.64	19.65	21	3034	7901	63478066
Instillation site pain	61.17	19.65	13	3042	891	63485076
Breath sounds abnormal	60.66	19.65	22	3033	10951	63475016
Eye discharge	56.54	19.65	18	3037	6045	63479922
Cardiac murmur	51.19	19.65	21	3034	14531	63471436
Eye pruritus	49.33	19.65	22	3033	18649	63467318
Erythema of eyelid	49.18	19.65	13	3042	2273	63483694
Dry eye	48.51	19.65	28	3027	40733	63445234
Presyncope	46.73	19.65	24	3031	27761	63458206
Eosinophilia	45.17	19.65	22	3033	22734	63463233
Nasal congestion	38.56	19.65	29	3026	65631	63420336
Vision blurred	37.88	19.65	33	3022	91891	63394076
Chronic obstructive pulmonary disease	33.11	19.65	26	3029	62660	63423307
Scleral hyperaemia	30.22	19.65	6	3049	293	63485674
Anaemia vitamin B12 deficiency	28.20	19.65	6	3049	413	63485554
Keratitis	27.19	19.65	9	3046	3413	63482554
Eyelids pruritus	26.99	19.65	7	3048	1135	63484832
Lacrimation increased	26.76	19.65	15	3040	20616	63465351
Productive cough	26.64	19.65	23	3032	63185	63422782
Visual acuity reduced	25.97	19.65	15	3040	21811	63464156
Photophobia	23.35	19.65	13	3042	17622	63468345
Upper respiratory tract infection	23.33	19.65	24	3031	82023	63403944
Eye swelling	22.16	19.65	14	3041	23904	63462063
Intraocular pressure increased	22.15	19.65	9	3046	6069	63479898
Eyelid irritation	21.30	19.65	5	3050	538	63485429
Eyelid oedema	20.39	19.65	10	3045	10469	63475498
Blood sodium abnormal	19.92	19.65	5	3050	712	63485255

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Appendicolith	142.25	31.79	42	2129	8559	34946201
Appendicitis	119.81	31.79	42	2129	14765	34939995
Ventricular fibrillation	101.90	31.79	42	2129	22912	34931848
Stress	100.10	31.79	45	2126	30302	34924458
Blood phosphorus increased	98.93	31.79	31	2140	7690	34947070
Cardiogenic shock	95.90	31.79	42	2129	26576	34928184
Myasthenia gravis	93.68	31.79	29	2142	6911	34947849
Ocular procedural complication	83.64	31.79	12	2159	55	34954705
Blood uric acid increased	80.48	31.79	28	2143	9596	34945164
Ascites	76.33	31.79	43	2128	46528	34908232
Abdominal distension	69.76	31.79	44	2127	58448	34896312
Dry mouth	69.59	31.79	35	2136	30130	34924630
Blood cholesterol increased	59.92	31.79	28	2143	20515	34934245
Hyponatraemia	58.18	31.79	45	2126	82646	34872114
Multiple organ dysfunction syndrome	56.78	31.79	43	2128	76523	34878237
Constipation	47.46	31.79	50	2121	136932	34817828
Iron deficiency	42.45	31.79	15	2156	5366	34949394
Hyperphosphataemia	41.31	31.79	14	2157	4423	34950337
Incorrect route of product administration	39.49	31.79	19	2152	14826	34939934
Abdominal pain	38.60	31.79	49	2122	163569	34791191
Sepsis	37.91	31.79	49	2122	166512	34788248
General physical health deterioration	37.75	31.79	43	2128	128226	34826534
Keratitis	37.21	31.79	10	2161	1441	34953319
Drug therapy	34.69	31.79	9	2162	1132	34953628
Neuralgia	33.24	31.79	17	2154	15096	34939664
Hypophosphataemia	32.03	31.79	15	2156	11011	34943749

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Appendicolith	146.46	22.74	42	4437	8509	79731400
Eye irritation	120.94	22.74	45	4434	20636	79719273
Appendicitis	109.82	22.74	42	4437	20752	79719157
Blood phosphorus increased	96.96	22.74	32	4447	10315	79729594
Ventricular fibrillation	92.43	22.74	42	4437	31884	79708025
Myasthenia gravis	88.85	22.74	30	4449	10369	79729540
Ocular procedural complication	86.20	22.74	16	4463	465	79739444
Cardiogenic shock	84.46	22.74	43	4436	41871	79698038
Blood uric acid increased	77.82	22.74	29	4450	13331	79726578
Stress	65.89	22.74	46	4433	79566	79660343
Ascites	63.32	22.74	44	4435	75518	79664391
Ocular hyperaemia	62.87	22.74	31	4448	28175	79711734
Chronic obstructive pulmonary disease	60.71	22.74	45	4434	85374	79654535
Pneumonia viral	57.46	22.74	21	4458	9137	79730772
Keratitis	55.51	22.74	17	4462	4305	79735604
Multiple organ dysfunction syndrome	53.08	22.74	48	4431	120198	79619711
Breath sounds abnormal	49.32	22.74	22	4457	15962	79723947
Dry mouth	48.71	22.74	40	4439	87979	79651930
Foreign body sensation in eyes	47.92	22.74	13	4466	2144	79737765
Cardiac murmur	46.35	22.74	21	4458	15803	79724106
Abdominal distension	45.55	22.74	44	4435	119606	79620303
Eye pain	41.46	22.74	26	4453	37552	79702357
Erythema of eyelid	41.21	22.74	12	4467	2558	79737351
Instillation site pain	39.66	22.74	9	4470	714	79739195
Eye discharge	38.46	22.74	14	4465	6020	79733889
Hyperphosphataemia	37.70	22.74	14	4465	6362	79733547
Hyponatraemia	35.93	22.74	47	4432	177801	79562108
Drug therapy	35.12	22.74	9	4470	1192	79738717
Presyncope	34.58	22.74	24	4455	41030	79698879
Iron deficiency	33.95	22.74	15	4464	10639	79729270
Incorrect route of product administration	33.18	22.74	22	4457	34907	79705002
Blood cholesterol increased	32.24	22.74	31	4448	83689	79656220
Analgesic therapy	31.66	22.74	8	4471	1001	79738908
Sleep disorder therapy	31.55	22.74	8	4471	1016	79738893
Visual acuity reduced	31.53	22.74	20	4459	29449	79710460
Nasal congestion	30.72	22.74	29	4450	76523	79663386
Sepsis	30.00	22.74	54	4425	269374	79470535
Dry eye	29.73	22.74	21	4458	36910	79702999
Corneal disorder	29.37	22.74	9	4470	2282	79737627
Constipation	29.33	22.74	55	4424	282995	79456914
Corneal epithelium defect	29.13	22.74	7	4472	712	79739197
Eosinophilia	28.03	22.74	22	4457	45323	79694586
Hypophosphataemia	27.71	22.74	16	4463	19897	79720012
Ulcerative keratitis	25.16	22.74	9	4470	3680	79736229
Upper respiratory tract infection	24.75	22.74	28	4451	91140	79648769
Neuralgia	24.62	22.74	18	4461	33366	79706543
Anaemia vitamin B12 deficiency	23.51	22.74	6	4473	782	79739127
General physical health deterioration	23.11	22.74	49	4430	275189	79464720
Somnolence	22.97	22.74	45	4434	238936	79500973
Vision blurred	22.95	22.74	29	4450	105869	79634040

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
CHEBI has role	CHEBI:48356	protogenic solvent
CHEBI has role	CHEBI:50904	alergeno
CHEBI has role	CHEBI:75771	Mus musculus metabolites
CHEBI has role	CHEBI:76967	human xenobiotic metabolites
MeSH PA	D010592	Pharmaceutic Aids
MeSH PA	D014677	Pharmaceutical Vehicles
MeSH PA	D012997	Solvents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Tear film insufficiency	indication	46152009
Keratoconjunctivitis sicca	off-label use	302896008	DOID:12895

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4017526	VUID
N0000145910	NUI
D00078	KEGG_DRUG
4017526	VANDF
C0072225	UMLSCUI
CHEBI:16997	CHEBI
CHEMBL286398	ChEMBL_ID
D019946	MESH_DESCRIPTOR_UI
DB01839	DRUGBANK_ID
6DC9Q167V3	UNII
1030	PUBCHEM_CID
34693	RXNORM
NOCODE	MMSL
002468	NDDF
13668001	SNOMEDCT_US
411259004	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Systane Lubricant	HUMAN OTC DRUG LABEL	2	0065-0429	SOLUTION/ DROPS	3 mg	OPHTHALMIC	OTC monograph final	13 sections
Systane Lubricant	HUMAN OTC DRUG LABEL	2	0065-0429	SOLUTION/ DROPS	3 mg	OPHTHALMIC	OTC monograph final	13 sections
Systane	HUMAN OTC DRUG LABEL	2	0065-0431	SOLUTION/ DROPS	3 mg	OPHTHALMIC	OTC monograph final	13 sections
Systane	HUMAN OTC DRUG LABEL	2	0065-0431	SOLUTION/ DROPS	3 mg	OPHTHALMIC	OTC monograph final	13 sections
Systane	HUMAN OTC DRUG LABEL	2	0065-0454	GEL	3 mg	OPHTHALMIC	OTC monograph final	13 sections
Systane	HUMAN OTC DRUG LABEL	2	0065-0454	GEL	3 mg	OPHTHALMIC	OTC monograph final	13 sections
Systane COMPLETE	HUMAN OTC DRUG LABEL	1	0065-0481	SOLUTION/ DROPS	0.06 mg	OPHTHALMIC	OTC monograph final	12 sections
Systane COMPLETE	HUMAN OTC DRUG LABEL	1	0065-0481	SOLUTION/ DROPS	0.06 mg	OPHTHALMIC	OTC monograph final	12 sections
Systane Ultra	HUMAN OTC DRUG LABEL	2	0065-1431	SOLUTION/ DROPS	3 mg	OPHTHALMIC	OTC monograph final	13 sections
Systane Ultra	HUMAN OTC DRUG LABEL	2	0065-1431	SOLUTION/ DROPS	3 mg	OPHTHALMIC	OTC monograph final	13 sections
Systane Ultra	HUMAN OTC DRUG LABEL	2	0065-1431	SOLUTION/ DROPS	3 mg	OPHTHALMIC	OTC monograph final	13 sections
Systane Ultra	HUMAN OTC DRUG LABEL	2	0065-1431	SOLUTION/ DROPS	3 mg	OPHTHALMIC	OTC monograph final	13 sections
SystaneULTRA	HUMAN OTC DRUG LABEL	2	0065-1432	SOLUTION/ DROPS	3 mg	OPHTHALMIC	OTC monograph final	12 sections
SystaneULTRA	HUMAN OTC DRUG LABEL	2	0065-1432	SOLUTION/ DROPS	3 mg	OPHTHALMIC	OTC monograph final	12 sections
Systane Balance	HUMAN OTC DRUG LABEL	1	0065-1433	EMULSION	0.06 mg	OPHTHALMIC	OTC monograph final	12 sections
Systane Balance	HUMAN OTC DRUG LABEL	1	0065-1433	EMULSION	0.06 mg	OPHTHALMIC	OTC monograph final	12 sections
Systane Balance	HUMAN OTC DRUG LABEL	1	0065-1433	EMULSION	0.06 mg	OPHTHALMIC	OTC monograph final	12 sections
SYSTANE HYDRATION PF PRESERVATIVE FREE	HUMAN OTC DRUG LABEL	2	0065-1437	SOLUTION/ DROPS	3 mg	OPHTHALMIC	OTC monograph final	13 sections
SYSTANE HYDRATION PF PRESERVATIVE FREE	HUMAN OTC DRUG LABEL	2	0065-1437	SOLUTION/ DROPS	3 mg	OPHTHALMIC	OTC monograph final	13 sections
Systane Ultra Preservative Free	HUMAN OTC DRUG LABEL	2	0065-1507	SOLUTION/ DROPS	3 mg	OPHTHALMIC	OTC monograph final	12 sections
Systane Ultra Preservative Free	HUMAN OTC DRUG LABEL	2	0065-1507	SOLUTION/ DROPS	3 mg	OPHTHALMIC	OTC monograph final	12 sections
Systane COMPLETE PF	HUMAN OTC DRUG LABEL	1	0065-1509	SOLUTION/ DROPS	0.06 mg	OPHTHALMIC	OTC monograph final	12 sections
Systane COMPLETE PF	HUMAN OTC DRUG LABEL	1	0065-1509	SOLUTION/ DROPS	0.06 mg	OPHTHALMIC	OTC monograph final	12 sections
SYSTANE HYDRATION PF PRESERVATIVE FREE	HUMAN OTC DRUG LABEL	2	0065-1510	SOLUTION/ DROPS	3 mg	OPHTHALMIC	OTC monograph final	13 sections
SYSTANE HYDRATION PF PRESERVATIVE FREE	HUMAN OTC DRUG LABEL	2	0065-1510	SOLUTION/ DROPS	3 mg	OPHTHALMIC	OTC monograph final	13 sections
SYSTANE HYDRATION PF PRESERVATIVE FREE	HUMAN OTC DRUG LABEL	2	0065-1510	SOLUTION/ DROPS	3 mg	OPHTHALMIC	OTC monograph final	13 sections
Systane COMPLETE PF	HUMAN OTC DRUG LABEL	1	0065-1530	SOLUTION/ DROPS	0.06 mg	OPHTHALMIC	OTC monograph final	12 sections
Systane COMPLETE PF	HUMAN OTC DRUG LABEL	1	0065-1530	SOLUTION/ DROPS	0.06 mg	OPHTHALMIC	OTC monograph final	12 sections
Systane COMPLETE PF	HUMAN OTC DRUG LABEL	1	0065-1530	SOLUTION/ DROPS	0.06 mg	OPHTHALMIC	OTC monograph final	12 sections
GenTeal Tears Gel Drops	HUMAN OTC DRUG LABEL	2	0065-8067	GEL	3 mg	OPHTHALMIC	OTC monograph final	13 sections